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Summary: Purpose: SCN1A is the most clinically relevant
epilepsy gene, most mutations lead to severe myoclonic epilepsy
of infancy (SMEI) and generalized epilepsy with febrile seizures
plus (GEFS+). We studied 132 patients with epilepsy syndromes
with seizures precipitated by fever, and performed phenotype–
genotype correlations with SCN1A alterations.
Methods: We included patients with SMEI including border-
line SMEI (SMEB), GEFS+, febrile seizures (FS), or other
seizure types precipitated by fever. We performed a clinical
and genetic study focusing on SCN1A, using dHPLC, gene se-
quencing, and MLPA to detect genomic deletions/duplications
on SMEI/SMEB patients.
Results: We classified patients as: SMEI/SMEB = 55;
GEFS+ = 26; and other phenotypes = 51. SCN1A analysis by
dHPLC/sequencing revealed 40 mutations in 37 SMEI/SMEB
(67%) and 3 GEFS+ (11.5%) probands. MLPA showed genomic
deletions in 2 of 18 SMEI/SMEB. Most mutations were de novo
(82%). SMEB patients carrying mutations (8) were more likely to
have missense mutations (62.5%), conversely SMEI patients (31)
had more truncating, splice site or genomic alterations (64.5%).
SMEI/SMEB with truncating, splice site or genomic alterations
had a significantly earlier age of onset of FS compared to those
with missense mutations and without mutations (p = 0.00007,
ANOVA test). None of the remaining patients with seizures pre-
cipitated by fever carried SCN1A mutations.
Conclusion: We obtained a frequency of 71% SCN1A abnor-
malities in SMEI/SMEB and of 11.5% in GEFS+ probands.
MLPA complements DNA sequencing of SCN1A increasing the
mutation detection rate. SMEI/SMEB with truncating, splice site
or genomic alterations had a significantly earlier age of onset
of FS. This study confirms the high sensitivity of SCN1A for
SMEI/SMEB phenotypes. Key Words: SMEI—GEFS+—
SCN1A—Fever-provoked seizures—MLPA.
Mutations in the gene coding for the α1 subunit of
the neuronal sodium channel (SCN1A) have been asso-
ciated with various types of epilepsy. SCN1A abnormal-
ities have been found in about 5–10 % of generalized
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epilepsy with febrile seizures plus (GEFS+) families, but
the overwhelming majority of known SCN1A mutations
lead to severe myoclonic epilepsy of infancy (SMEI) in-
cluding borderline SMEI (SMEB). From 35% to 100% of
SMEI/SMEB patients carry SCN1A mutations that are de
novo in most (Mulley et al., 2005).
Clinical analysis of the phenotypes shows that the
first clinical manifestations of mutations in SCN1A are
recurrent, often prolonged, seizures provoked by fever in
infancy. This association suggests that, in clinical prac-
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tice, mutations in SCN1A should be suspected in every
child with new onset, recurrent seizures precipitated by
fever.
With the aim of better defining the spectrum of phe-
notypes that might be associated with SCN1A mutations,
we performed a clinical and genetic study focusing on
SCN1A screening in patients in whom fever was a pre-
cipitant factor for seizures. We studied three subgroups
of patients with: (1) SMEI/SMEB, (2) GEFS+, and (3) a
group of patients in whom febrile seizures (FS) or seizures
precipitated by fever had occurred although they were not
characteristic of their epilepsy syndrome.
To increase the power of detecting SCN1A abnormali-
ties we applied a new technique named multiplex ligation-
dependent probe amplification (MPLA), searching for ge-
nomic abnormalities that are not identifiable with DNA
sequencing.
METHODS
Patients recruitment
We recruited subjects with a clinical diagnosis of
SMEI/SMEB, GEFS+ and either focal or generalized id-
iopathic epilepsies whose seizures were increased dur-
ing febrile episodes as well as patients with classical FS.
Patients were collected in an international collaborative
study. Informed consent was obtained from parents or
legal guardians. The study was approved by the Ethical
committee of the IRCCS Stella Maris Foundation.
Clinical assessment
Clinical history, genealogical information and family
trees, EEG recordings, and MRI were collected from
the parents and/or other relatives for patients seen at
the Epilepsy, Neurophysiology and Neurogenetic Unit,
Stella Maris Foundation, Pisa, Italy. For patients referred
from other centers, medical records were collected and
reviewed.
Epileptic seizures and epilepsy syndrome diagnoses
were performed, prior to the molecular genetic study, ac-
cording to the clinical criteria established by the Inter-
national League Against Epilepsy (ILAE, 1981; 1989;
Engel, 2001). Classical SMEI was diagnosed following
the criteria described by Dravet et al. (2002). The term
SMEB was used for cases without a number of the key
features of SMEI (Oguni et al., 2001; Dravet et al., 2002;
Fukuma et al., 2004).
GEFS+ phenotypes were diagnosed following the clin-
ical criteria described by Scheffer and Berkovic 1997
(Scheffer and Berkovic, 1997; Singh et al., 1999). By def-
inition, a diagnosis of GEFS+ requires a positive fam-
ily history. However, patients with FS extending beyond
6 years and/or with afebrile seizures (FS+) without a
family history were also included as de novo mutations
are known to occur in familial epilepsies (Phillips et al.,
2000). Myoclonic astatic epilepsy (MAE) was considered
as sporadic if no other family members had seizures or
it was included in the GEFS+ spectrum when occurring
in families. Patients in whom, despite clinical informa-
tion, a diagnosis could not be made, were designated as
“unclassified epilepsy.” Outside SMEI and GEFS+ syn-
dromes, fever was considered as an important provoking
factor when the patients’ habitual seizures increased by at
least 50% during febrile episodes.
Molecular analysis
The coding regions of the SCN1A gene were analyzed
by denaturing high performance liquid chromatography
(dHPLC) (Transgenomic Inc., Cheshire, U.K.). Abnormal
profiles observed on dHPLC screening were subsequently
sequenced (ABI3100avant; Applied Biosystems, Foster
City CA, U.S.A.).
Multiplex ligation-dependent probe amplification
assay (MPLA)
SMEI/SMEB patients without SCN1A mutations upon
dHPLC or sequencing were analyzed with MLPA assay,
aiming to uncover genomic deletions/duplications. The
MLPA SCN1A kit (SALSA˙P137, MRC-Holland, Ams-
terdam, The Netherlands) contains 25 paired-probes from
the SCN1A region (covering 25/26 exons) and 14 con-
trol probes specific for other chromosomes. Screening
was performed according to the manufacturer’s proto-
col. MLPA products were separated on an automated se-
quencer (Applied Biosystems, Foster City CA, U.S.A.)
and sized using ROX-500 (Applied Biosystems, Foster
City CA, U.S.A.). Peaks corresponding to SCN1A ex-
ons and control probes were identified according to their
size. Peak areas were exported into an Excel Spreadsheet
and normalized as previously reported (Hogervorst et al.,
2003). Values of 1.7–2.3 indicate normal results whereas,
values <1.7 or >2.3, indicate a deletion or a duplication.
Alterations were confirmed with a second MLPA reac-
tion.
Genotype–phenotype correlations
Based on epilepsy syndromes, the 132 patients were di-
vided into: (1) SMEI/SMEB, (2) GEFS+, and (3) other
phenotypes. A clinical analysis focused on seizure types
and age of seizures onset, with particular attention to
seizures precipitated by fever, was performed in the three
groups. Based on previous studies of genotype–phenotype
correlations (Ohmori et al., 2003; Ceulemans et al., 2004;
Fukuma et al., 2004) we further subdivided SMEI/SMEB
probands in three subgroups according to SCN1A anal-
ysis: (a) truncating, splicing alterations, and genomic
alterations, (b) missense mutations, and (c) no genomic
alterations. ANOVA test was used for statistical analysis
to evaluate differences of age of seizure onset between the
three groups.
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To evaluate the existence of hotspot regions, where mu-
tations of SCN1A are more likely to fall, we compared the
number of the identified mutations in each exon (includ-
ing 10 nucleotides up and down stream the exon) to the
number of expected mutations using the Fisher’s exact
test. We performed the same test to evaluate the loca-
tion of SCN1A mutations according to their coding pro-
tein domain: N-terminal + DI; Loop 1; DII; Loop 2; DIII;
Loop 3 and DIV + C-term.
RESULTS
A total of 132 probands, 74 females and 58 males were
studied. The mean age at the time of the study was 9 years
(median 6.5 ranging from 1 to 38). Epilepsy phenotypes
of the 132 probands are shown on Table 1.
SCN1A analysis
(a) dHPLC/sequencing
dHPLC analysis and sequencing of SCN1A in the
132 patients revealed 40 mutations: 19 missense, 5 non-
sense, 10 frameshift, 4 splice site mutations (one iden-
tified twice) and two silent nucleotide substitutions that
in silico seemed to modify the mRNA splicing process
(Fig. 1A and B). Molecular analysis of the 68 available
parents showed that 28 mutations were de novo and 6
were inherited (two truncating and four missense muta-
tions) (Tables 2 and 3, supplementary material). The posi-
tion of the missense mutations within the SCN1A protein
is shown in Fig. 2.
TABLE 1. Epilepsy phenotypes of the 132 patients screened
for SCN1A
Syndromic No. of SCN1A
phenotypes patients alterations
1) SMEI/SMEB 55 39 (71%)
2) GEFS+ spectrum 26 3 (11,5%)
3) Other phenotypes
Sporadic MAE 3 0
FS 10 0
CAE 7 0
CAE> JME 2 0
JAE 2 0
JME 1 0
IGE-TCS 2 0
Benign infantile convulsions 2 0
Atypical BRE 1 0
Idiopathic fever-sensitive focal epilepsy 3 0
Uncl epilepsy with fever-sensitive sz 18 0
Total 132 42 (32%)
BRE, benign rolandic epilepsy; CAE, childhood absence epilepsy;
FS, febrile seizures; IGE-TCS, idiopathic generalized epilepsy with
tonic–clonic seizures; GEFS+, generalized epilepsy with febrile seizures
plus; JME, juvenile myoclonic epilepsy; JAE, juvenile absence epilepsy;
MAE, myoclonic astatic epilepsy; SMEI, severe myoclonic epilepsy of
infancy; SMEB, borderline severe myoclonic epilepsy of infancy; sz,
seizures; Uncl, unclassified.
(b) Multiplex ligation-dependent probe amplification
(MLPA)
MLPA analysis revealed genomic deletions of SCN1A
in 2 of 18 patients with SMEI/SMEB (11%) without
SCN1A mutations on dHPLC and/or sequencing. The
first patient carried a deletion of the entire SCN1A
gene, in the second patient exons 12 to 14 were deleted
(Table 2, supplementary material). Both patients had clas-
sical SMEI.
Distribution of the SCN1A alterations among the
epilepsy syndromes
(1) Severe myoclonic epilepsy of infancy
(SMEI/SMEB)
We studied 55 patients (27 females and 28 males) with
a clinical diagnosis of SMEI (40 patients) and SMEB
(15 patients). Mean age at the time of the study was 9.5
years (median 8.6 ± 5.1, ranging from 2.5 to 20.8). Among
the 55 patients with SMEI/SMEB, 39 (71%) had SCN1A
abnormalities.
(a) SCN1A truncating mutations, splicing alterations,
or genomic alterations.
SCN1A truncating, splice site or genomic alterations
were identified in 23 patients (59% of patients with muta-
tions) of whom 20 had classical SMEI and 3 had SMEB
(Fig. 1A). All patients had recurrent FS and in most of
them FS was the first clinical expression occurring be-
tween the fourth to fifth months of life (mean 4.6 months;
median 4; range 2–9). All patients had mild-to-severe cog-
nitive impairment. A family history for seizures, including
FS, was present in 11 (48%) probands and in one of them
there was a bilineal occurrence of seizures. The sister of
a patient with SMEI had a clinical history also consistent
with SMEI. Their father had FS from infancy to child-
hood. (Patients’ clinical details are reported on Table 2,
supplementary material).
(b) SCN1A missense mutations
Missense mutations were found in 16 patients (43% of
patients with mutations) (Fig. 1B). A diagnosis of SMEI
was made in 11 probands, whereas five had SMEB. Re-
current, often prolonged, FS were seen in all patients, with
a mean age at onset of 6.7 months (median 7; range 3–12).
All patients had mild-to-severe cognitive impairment. A
family history of seizures, including FS, was present in
9 of 16 (56%) patients, and in 2 of 9 there was a bilin-
eal occurrence of seizures. (Patients’ clinical details are
reported on Table 3, supplementary material)
(c) Without SCN1A mutations
Molecular analysis did not reveal SCN1A mutations
in 16 patients with SMEB (7) and SMEI (9). FS begin-
ning around age of 10.7 months (median 9.5; range 4–
24 months) occurred in all patients. Borderline cognitive
functions were seen in five patients, and the remaining 11
had mild-to-severe cognitive impairment. A family history
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FIG. 1. (A) Graphic representation of the SCN1A protein showing the location of the truncating and splice site mutations. In the upper
part of the figure are reported mutations leading to truncated SCN1A protein and to mRNA splicing alteration (underlined), associated with
severe myoclonic epilepsy of infancy; in the lower part are reported the truncating mutations associated with borderline severe myoclonic
epilepsy of infancy (SMEB). (B) Graphic representation of the SCN1A protein showing the location of the missense mutations. In the upper
part of the figure are reported missense mutations associated with severe myoclonic epilepsy of infancy (SMEI); in the lower part are
reported the missense mutations associated with borderline severe myoclonic epilepsy of infancy (SMEB) and with generalized epilepsy
with febrile seizures plus (GEFS+).
of seizures, including FS, was present in 10 (62.5%)
probands.
(2) Generalized epilepsy with febrile seizure plus
(GEFS+) or FS+.
A diagnosis of GEFS+ was made in 26 patients
(15 females and 11 males) aged from 1 to 26 years (mean 8;
median 6.5). FS occurred in all patients with a mean age at
onset of 17 months (median 12, range 5–60). Afebrile
tonic–clonic seizures occurred in 19 patients with
mean age at onset of 43 months (median 19; range
3–108 months). Other seizure types included: myoclonic
(7 patients), absences (2 patients), myoclonic-astatic
(6 patients), and partial seizures (9 patients). A family
history for seizures, including FS, was present in 25.
Of the 26 patients with GEFS+ spectrum, 3 (11.5%)
harbored SCN1A mutations (Fig. 1B). The available fam-
ily history of these three patients was limited to the
parents-proband triad. In the first proband with FS+ and a
left malformed hippocampus, the SCN1A mutation was in-
herited from the father who had classical FS. In the third
proband with MAE the mutation was transmitted from
the mother with FS+. The second proband harbored a de
novo mutation, no family history of seizures was detected
(Clinical details of the 3 patients are reported on Table 4,
supplementary material).
(3) Other phenotypes
Classical febrile seizures (Table 1) were diagnosed in
10 patients; mean age of FS onset was 15 months (median
12.5; range 8–31). One patient had right hippocampal scle-
rosis (HS) on MRI and a mild cognitive deficit. A family
history of epilepsy was detected in nine probands. None
had SCN1A mutations.
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FIG. 2. Graphic representation showing the location of the mis-
sense mutation according to protein domains: N or C terminal;
pore region; insulating region; voltage sensor; interdomain and
other regions. Within protein domains, mutations have also been
subdivided according to the phenotype: white for GEFS+, gray for
SMEB, and black for SMEI.
Idiopathic generalized epilepsies (Table 1) with an-
tecedents of FS were documented in 14 patients, none
carrying SCN1A mutations. A family history of epilepsy,
including FS, was detected in 11 of 14 probands. Three
patients had sporadic myoclonic astatic epilepsy and
SCN1A screening was negative.
The remaining 24 patients had various epilepsy phe-
notypes (Table 1) and most (18), despite clinical and
EEG information, could not be classified. These patients
had either focal or generalized seizures, or both, which
exhibited increase in frequency (>50%) during febrile
episodes. Mean age at seizure onset was 20 months (me-
dian 17, range: neonatal period: 84 months). A family
history of epilepsy was noticed in six probands, in five pa-
tients genealogical information was not available. None
had SCN1A mutations.
Genotype–phenotype correlations
Age at onset of FS showed a highly significant dif-
ference (p = 0.00007; ANOVA test) between the three
groups of SMEI/SMEB patients with: (a) SCN1A trun-
cating mutations, splicing alterations, or genomic alter-
ations, (b) SCN1A missense mutations, and (c) no SCN1A
abnormalities. Patients with truncating mutations had an
earlier onset, around the fifth month of age, those with
missense mutations had a later onset of FS, around the
seventh month, and finally, individuals without SCN1A
mutations had an age of onset around the tenth month of
life. For the remaining seizure types—febrile and afebrile
status, afebrile tonic–clonic or hemiclonic, myoclonic,
absence and partial seizures—there were no significant
differences in age at seizure onset between the three
groups.
The statistical analysis, comparing the number of iden-
tified mutations in each exon to the number of expected
mutations, did not show significant differences between
exons (p > 0.05) (Fisher’s exact test). The highest num-
ber of mutations (10/40) was found in exon 26. These data
however, did not reach a significant p-value because exon
26 is a large exon, therefore carrying a higher chance of
being hit by mutations. Likewise, when performing the
same analysis grouping the exons according to their cod-
ing protein domain (N-terminal + DI; Loop 1; DII; Loop
2; DIII; Loop 3 and DIV + C-term) there were no signif-
icant differences between domains (p > 0.05).
DISCUSSION
Mutation rates
In our cohort of 132 patients with idiopathic epilepsies
with seizures precipitated by fever in infancy and early
childhood, classical SMEI was diagnosed in 40 (30%),
SMEB in 15 (11%), and GEFS+ in 26 (19,6%). Muta-
tions and genomic deletions of SCN1A were identified in
31 patients (77.5%) with classical SMEI and in 8 (53%)
with SMEB. We obtained an overall frequency of 71%
SCN1A abnormalities patients, which is intermediate be-
tween the lowest and the highest previously reported per-
centages for SMEI/SMEB (35–100%) ( Claes et al., 2001;
Ohmori et al., 2002; Fujiwara et al., 2003; Nabbout et al.,
2003; Sugawara et al., 2002; Wallace et al., 2003). It is
likely that some differences in detection rate can be at-
tributed to ascertainment bias due to controversial aspects
in the diagnosis of SMEI. We based our clinical classifica-
tion predominantly on age of onset and on the occurrence
of prolonged hemiclonic or generalized seizures occur-
ring with fever. The results of SCN1A analysis supported
our diagnostic criteria. The 31 SMEI patients carrying
mutations, manifested FS at onset, followed by febrile or
afebrile seizures evolving into status epilepticus in most,
whereas myoclonic seizures were noticed only in 27 of 40
(67.5%) patients with mutations.
Genomic deletions of SCN1A in SMEI/SMEB
MLPA, performed in 18 SMEI/SMEB patients, showed
genomic deletions in two of them (11%). This finding
indicates that in a subset of SMEI/SMEB patients with-
out SCN1A molecular abnormality, MLPA increases the
power to detect SCN1A alterations. Using FISH, MAQ
or MLPA, SCN1A deletions, cryptic chromosome dele-
tions encompassing the SCN1A locus have been recently
identified in 8–27% of patients with SMEI (Madia et al.,
2006; Mulley et al., 2006; Suls et al., 2006). MLPA is
a rapid and cost-effective complement to DNA sequenc-
ing, increasing the overall mutation detection rate and
should be considered systematically if DNA sequencing
fails to demonstrate SCN1A mutations. The percentage
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of genomic abnormalities identified with MPLA in our
series of SMEI/SMEB patients is similar to previously re-
ported studies (Madia et al., 2006; Mulley et al., 2006;
Suls et al., 2006). Studies with higher number of patients
are needed to determine a more accurate deletion
frequency. Variability in the detection of SCN1A genomic
abnormalities might be due to patients’ ascertainment bias
and to different sensitivity of the methods used to un-
cover genomic abnormalities. For example, the study of
Madia et al. used a FISH analysis that allows the de-
tection of deletion/duplication larger than 50 kb (Pereira
et al., 2004; Madia et al., 2006). Such large genomic alter-
ations, involve SCN1A and other contiguous genes produc-
ing SMEI/SMEB with additional clinical features (Pereira
et al., 2004; Madia et al., 2006).
Is SMEI/SMEB an inherited disorder?
In this study, molecular analysis of the 32 SMEI/SMEB
probands in whom parents’ DNA was available, revealed
that 28 mutations were de novo (86%), whereas only 4
(14%) were inherited (one truncating, one splice site, and
two missense mutations). The inherited truncating muta-
tion was transmitted from a father who had a single seizure
(D1293delX1299 mutation). Literature review shows only
one other family in which SCN1A truncating mutation was
inherited from a mildly affected mother (Nabbout et al.,
2003). The second familial SCN1A splice site mutation
(IVS4 + 1 G>A) was also present in the proband’s sister,
whose phenotype was consistent with SMEI. Both sis-
ters’ had inherited the mutation from their father who had
had only FS from infancy to childhood and exhibited mo-
saicism (Marini et al., 2006). Mosaic germline mutations
of SCN1A have recently been identified in five additional
families with SMEI probands, suggesting a possible con-
tribution of mosaicism to individual and familial pheno-
typic variability (Depienne et al., 2006; Gennaro et al.,
2006; Morimoto et al., 2006).
In our cohort of SMEI/SMEB probands 56% had first-
or second-degree relatives with seizures, including FS,
favoring the hypothesis that SMEI might be an inherited
disorder (Nabbout et al., 2003; Wallace et al., 2003). How-
ever, high rates of family history of epilepsy and familial
occurrence of SMEI are hard to reconcile with the finding
that most SCN1A mutations in SMEI are de novo.
Genotype−phenotype correlations
We observed a mild predominance of truncating, splice
site, or genomic alterations (59%) over missense (41%)
mutations. Patients with SMEB were more likely to
have missense mutations (62.5%). Conversely, patients
with classical SMEI had more truncating, splice site,
or genomic alterations (64.5%). Similarly to previous
studies, we found that missense mutations in the pore-
forming parts S5-S6 of the channel occurred in 10 of
16 SMEI/SMEB patients (62.5%) and only in 1 of 3 of
GEFS+ patients (Fig. 2).
Statistical analysis of the mean age of onset of FS
showed that patients with truncating mutations had the
earliest onset (5 months) followed by patients with mis-
sense mutations, having an intermediate onset (7 months),
and individuals without SCN1A mutations, showing the
latest age of onset (10 months). The difference between
the three groups was statistically significant (p = 0.0007).
It would be interesting studying larger series of patients
to determine whether truncating mutations, and therefore
earlier FS onset, carry a higher chance of developing a
more severe epileptic encephalopathy.
Only 6 of 39 of the mutations identified in our series
had been previously described. The highest number of
mutations (10/40) was found in exon 26, which is the
largest exon. However no statistically significant p-value
(Fisher’s exact test) indicative of a hotspot was reached.
GEFS+ and SCN1A mutations
Among GEFS+ phenotypes the rate of SCN1A muta-
tions was 11.5%. The W1204R mutation identified in a
child with FS+ and in his father had previously been re-
ported (Escayg et al., 2001), and Spampanato et al. showed
that this mutation causes an alteration of the voltage-
dependent channel gating that could result in neuronal
hyperexcitability (Spampanato et al., 2003). The Ser74Pro
missense mutation identified in a patient with FS+ is the
first de novo mutation described in GEFS+.
SCN1A and other phenotypes
None of the patients with idiopathic epilepsies with
seizures precipitated by fever besides SMEI/SMEB and
GEFS+ carried SCN1A mutations. Therefore, SCN1A is
not likely to cause seizures provoked by fever outside the
SMEI/SMEB and GEFS+ spectrum.
CONCLUSIONS
SCN1A is the most relevant epilepsy gene with the
largest number of epilepsy-related mutations so far iden-
tified. The high correlation between SMEI/SMEB and
SCN1A mutations suggests a phenotypic specificity of
SCN1A. However, SMEI/SMEB represent a very small
proportion of children with recurrent febrile seizures in a
population, thus this study does not address the issue of di-
agnostic specificity from a population perspective. We do
not know whether SCN1A also plays a role in other com-
mon epilepsy syndromes without febrile seizures, which
were not examined at all in our study.
The high rate of epilepsy in families of probands with
SMEI suggests that, in addition to SCN1A mutations, other
genetic factors might play a role in the expression of the
epilepsy phenotypes. SCN1A mosaic mutations should
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also be taken into account, at least in some cases, as a
possible explanation for familial phenotypic variability.
MLPA assay might be a useful tool to uncover genomic
deletions/duplications and to increase the power of discov-
ering SCN1A abnormalities in SMEI/SMEB. What causes
SMEI when there is no detectable SCN1A involvement re-
mains to be identified.
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